The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Takeda Pharmaceutical’s new drug application (NDA) of Adcetris (brentuximab vedotin) 50mg intended to treat patients with CD30 positive relapsed or refractory hodgkin lymphoma (HL) or relapsed or refractory anaplastic large cell lymphoma (ALCL).

Takeda head of the Oncology Therapeutic Area Unit Michael Vasconcelles said, “This approval brings us a step closer to providing a new treatment option to patients in Japan with relapsed or refractory HL and relapsed or refractory ALCL.”